Selective targeting of voltage-gated sodium channels to achieve analgesia: current status and future directions
Abstract
Abstract: Voltage-gated sodium channels (Nav) play a fundamental role in generating action potentials in excitable cells including nociceptors. Certain Nav subtypes are enriched in nociceptors, and human genetic data link them to pain disorders meaning that Navs have long been key analgesic drug targets. Developing small molecules to reduce channel conductance in a subtype-specific manner has been challenging but the Nav1.8 channel blocker, suzetrigine, has finally reached the clinic. Alternative approaches to selectively targeting Nav isoforms include anti-NaV aptamers and oligonucleotides, RNA editing, subtype-specific antibodies, and targeted protein degradation. Our hope, therefore, is that the recent approval of suzetrigine for acute pain will be but the first of a series of novel Nav targeting analgesics.
Read the paper
Related studies
- Noninvasive and Point-of-Care Surface-Enhanced Raman Scattering (SERS)-Based Breathalyzer for Mass Screening of Coronavirus Disease 2019 (COVID-19) under 5 min
- De Novo Transcriptome Analysis and Detection of Antimicrobial Peptides of the American Cockroach Periplaneta americana (Linnaeus)
- Molecular Characterization and Expression Profiling of Tomato GRF Transcription Factor Family Genes in Response to Abiotic Stresses and Phytohormones
- Assembly of Tight Junction Strands: Claudin-10b and Claudin-3 Form Homo Tetrameric Building Blocks that Polymerise in a Channel-Independent Manner
- Update of the Pompe variant database for the prediction of clinical phenotypes: Novel disease‐associated variants, common sequence variants, and results from newborn screening
- Machine Learning-Based SERS Chemical Space for Two-Way Prediction of Structures and Spectra of Untrained Molecules
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.